LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "ros1" as a keyword



Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors

Sign Up to like & get
recommendations! Published in 2024 at "Cancer Medicine"

DOI: 10.1002/cam4.7201

Abstract: The proto‐oncogene ROS1 encodes an intrinsic type I membrane protein of the tyrosine kinase/insulin receptor family. ROS1 facilitates the progression of various malignancies via self‐mutations or rearrangements. Studies on ROS1‐directed tyrosine kinase inhibitors have been… read more here.

Keywords: novel insights; regarding ros1; current treatment; insights regarding ... See more keywords

ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer

Sign Up to like & get
recommendations! Published in 2022 at "International Journal of Cancer"

DOI: 10.1002/ijc.34257

Abstract: c‐Ros oncogene 1, receptor tyrosine kinase (ROS1) genomic rearrangements have been reported previously in rare cases of colorectal cancer (CRC), yet little is known about the frequency, molecular characteristics, and therapeutic vulnerabilities of ROS1‐driven CRC.… read more here.

Keywords: ros1; crc; genomic rearrangements; ros1 genomic ... See more keywords

Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor.

Sign Up to like & get
recommendations! Published in 2019 at "Lung cancer"

DOI: 10.1016/j.lungcan.2018.12.016

Abstract: OBJECTIVES Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor and is prevalent among children and adolescents. In recent years, following the emergence of high-throughput sequencing techniques, rearrangements in genes, such as ALK, ROS1, NTRK,… read more here.

Keywords: tumor; myofibroblastic tumor; ros1; report ... See more keywords

Clinical significance of ROS1 5' deletions in non-small cell lung cancer.

Sign Up to like & get
recommendations! Published in 2019 at "Lung cancer"

DOI: 10.1016/j.lungcan.2019.07.017

Abstract: OBJECTIVES Patients harboring rearrangements of the ROS1 gene are eligible for first-line therapy with Crizotinib, which represents the best available treatment option. Diagnostic criteria, based on break-apart fluorescence in situ hybridization, were mirrored from ALK… read more here.

Keywords: crizotinib; fusion; lung cancer; ros1 ... See more keywords
Photo from wikipedia

A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.

Sign Up to like & get
recommendations! Published in 2020 at "Lung cancer"

DOI: 10.1016/j.lungcan.2020.03.019

Abstract: INTRODUCTION ROS1-rearranged non-small cell lung cancer (NSCLC) has demonstrated promising response to lorlatinib; however, no targeted therapy is available after failure of lorlatinib and information on acquired resistance mechanisms mediating lorlatinib resistance among ROS1-rearranged NSCLC… read more here.

Keywords: lorlatinib resistance; ros1; resistance; ros1 g2032 ... See more keywords
Photo from wikipedia

Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis.

Sign Up to like & get
recommendations! Published in 2021 at "Lung cancer"

DOI: 10.1016/j.lungcan.2021.05.019

Abstract: INTRODUCTION Increased thromboembolism (TE) has been reported in ALK+ and ROS1+ non-small cell lung cancer (NSCLC). MATERIALS AND METHODS Odds ratios (OR) and hazard ratios (HR) of TE were calculated from meta-analysis and time-to-event analysis… read more here.

Keywords: nsclc patients; analysis; alk ros1; ros1 ... See more keywords

Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK

Sign Up to like & get
recommendations! Published in 2017 at "Journal of chemical information and modeling"

DOI: 10.1021/acs.jcim.7b00019

Abstract: ROS1 and ALK are promising targets of anticancer drugs for non-small-cell lung cancer. Since they have 49% amide acid sequence homology in the kinases domain and 77% identity at the ATP binding area, some ALK… read more here.

Keywords: versus alk; inhibitor; alk; ros1 ... See more keywords

Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.

Sign Up to like & get
recommendations! Published in 2017 at "MedChemComm"

DOI: 10.1039/c6md00643d

Abstract: Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung cancer cells. Mitoxantrone can suppress… read more here.

Keywords: ros1 fusion; inhibitor ros1; ros1; cancer ... See more keywords

Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data

Sign Up to like & get
recommendations! Published in 2024 at "Expert Opinion on Investigational Drugs"

DOI: 10.1080/13543784.2024.2305131

Abstract: ABSTRACT Introduction While crizotinib and entrectinib have been approved to treat ROS1 fusion-positive (ROS1+) non-small-cell lung cancer (NSCLC), unmet needs remain. These unmet needs include treatment options for patients with resistance mutations and efficacious options… read more here.

Keywords: non small; lung cancer; cell lung; small cell ... See more keywords

Efficacy and safety of taletrectinib for treatment of ROS1 positive non-small cell lung cancer: A systematic review

Sign Up to like & get
recommendations! Published in 2025 at "Expert Opinion on Pharmacotherapy"

DOI: 10.1080/14656566.2025.2487150

Abstract: ABSTRACT Introduction Approximately 85% of all instances of lung cancer are non-small-cell lung cancer (NSCLC). Crizotinib and entrectinib are the preferred first line therapy for treating ROS1 fusion-positive NSCLC (ROS1+NSCLC). However, not all patients react… read more here.

Keywords: treatment; ros1; ros1 positive; lung cancer ... See more keywords
Photo from wikipedia

HGG-01. ENTRECTINIB IN RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS: UPDATED DATA IN CHILDREN AND ADOLESCENTS

Sign Up to like & get
recommendations! Published in 2020 at "Neuro-Oncology"

DOI: 10.1093/neuonc/noaa222.293

Abstract: Abstract STARTRK-NG (phase 1/2) is evaluating entrectinib, a CNS-penetrant oral, TRK/ROS1/ALK tyrosine kinase inhibitor, in patients read more here.

Keywords: solid tumors; cns tumors; cns; ros1 ... See more keywords